Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma

As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladanyi, Marc, Sanchez Vega, Francisco, Zauderer, Marjorie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/
https://www.ncbi.nlm.nih.gov/pubmed/30914057
http://dx.doi.org/10.1186/s13073-019-0631-0
_version_ 1783406773588197376
author Ladanyi, Marc
Sanchez Vega, Francisco
Zauderer, Marjorie
author_facet Ladanyi, Marc
Sanchez Vega, Francisco
Zauderer, Marjorie
author_sort Ladanyi, Marc
collection PubMed
description As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future trials. A new study finds that loss of the deubiquitinase BAP1 in PeM correlates with an inflammatory tumor microenvironment, suggesting that BAP1 status might identify PeM, and possibly PlM, patients who would benefit from ICI therapy.
format Online
Article
Text
id pubmed-6436227
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64362272019-04-08 Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma Ladanyi, Marc Sanchez Vega, Francisco Zauderer, Marjorie Genome Med Research Highlight As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future trials. A new study finds that loss of the deubiquitinase BAP1 in PeM correlates with an inflammatory tumor microenvironment, suggesting that BAP1 status might identify PeM, and possibly PlM, patients who would benefit from ICI therapy. BioMed Central 2019-03-26 /pmc/articles/PMC6436227/ /pubmed/30914057 http://dx.doi.org/10.1186/s13073-019-0631-0 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Ladanyi, Marc
Sanchez Vega, Francisco
Zauderer, Marjorie
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
title Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
title_full Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
title_fullStr Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
title_full_unstemmed Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
title_short Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
title_sort loss of bap1 as a candidate predictive biomarker for immunotherapy of mesothelioma
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227/
https://www.ncbi.nlm.nih.gov/pubmed/30914057
http://dx.doi.org/10.1186/s13073-019-0631-0
work_keys_str_mv AT ladanyimarc lossofbap1asacandidatepredictivebiomarkerforimmunotherapyofmesothelioma
AT sanchezvegafrancisco lossofbap1asacandidatepredictivebiomarkerforimmunotherapyofmesothelioma
AT zauderermarjorie lossofbap1asacandidatepredictivebiomarkerforimmunotherapyofmesothelioma

Ejemplares similares